

## Correction of Previously Communicated Press Release

Modus Therapeutics Holding AB (publ) today at 08:00 published a press release titled "Today the Exercise Period Begins for Modus Therapeutics Warrants Series 2025/2026". In the press release that was published, the warrants of series 2025/2026 issued in connection with guarantee compensation related to the rights issue were not included. Below is the press release in its entirety, including the warrants issued in connection with the guarantee compensation.

### Today the Exercise Period Begins for Modus Therapeutics Warrants Series 2025/2026

Today the exercise period begins for Modus Therapeutics Holding AB (publ)'s ("Modus Therapeutics" or the "Company") warrants series 2025/2026 (TO 2). The exercise period runs from 13 April 2026 through 24 April 2026. The last day of trading in warrants series 2025/2026 on Nasdaq First North Growth Market is 22 April 2026.

### Summary of Warrants Series 2025/2026

- Exercise period: 13 April 2026 – 24 April 2026.
- Subscription price: SEK 0.35 per new share.
- Issue volume: 28,563,198 warrants series 2025/2026. Upon full exercise of the warrants, 28,563,198 new shares will be issued in Modus Therapeutics and the Company will receive approximately SEK 10.0 million before issue costs.
- The last day of trading in warrants series 2025/2026 is 22 April 2026.

Upon full exercise of warrants series 2025/2026, the number of shares and votes in Modus Therapeutics will increase by 28,563,198 and the share capital will increase by SEK 1,713,791.88, from SEK 7,297,709.58 to SEK 9,011,501.46. This results in a dilution of approximately 19 percent based on the number of shares and votes in Modus Therapeutics after full exercise of all warrants series 2025/2026.

### Important Dates for Warrants Series 2025/2026

13 April 2026 – Exercise period begins

22 April 2026 – Last day of trading in warrants

24 April 2026 – Exercise period ends

27 April 2026 – Planned date for publication of exercise rate

5 May 2026 – Planned date for conversion of interim shares to shares

Subscription forms are available on Bergs Securities' website, [www.bergssecurities.se](http://www.bergssecurities.se). Full terms and conditions for warrants series 2025/2026 are available on Modus Therapeutics' website.

### **Offer to Warrant Holders – How to Exercise Your Warrants Series 2025/2026**

The last day of trading in warrants series 2025/2026 is 22 April 2026. To prevent your warrants from expiring, you must subscribe for new shares by exercising your warrants no later than 24 April 2026.

#### **Your warrants may be registered in one of two ways:**

1. In a securities account at a bank or with another custodian (for example Avanza or Nordnet), in an investment savings account (ISK), or in an endowment insurance policy (KF). In this case, your warrants are nominee-registered.
2. In a CSD account (a CSD account begins with three zeros). In this case, your warrants are directly registered.

#### **If Your Warrants Are Nominee-Registered**

Subscription and payment for new shares, through the exercise of warrants, shall be made to the respective bank or other custodian where the warrants are registered. Subscription and payment shall be made in accordance with the instructions provided by each such bank or custodian. Banks/custodians usually send a digital notification to the account holder; otherwise, it is usually sufficient to log in to the securities account from the first day of the exercise period in order to receive instructions on how to exercise warrants to subscribe for new shares. Please contact your bank or custodian if you cannot find these instructions. Note that banks and other custodians may set different deadlines for subscription; it is therefore recommended to contact your bank /custodian early during the exercise period for information on subscription and payment. Subscribed and paid shares may be registered in your securities account as "interim shares" or "IA" until the registration of the new shares is completed at the Swedish Companies Registration Office (Bolagsverket), at which point interim shares will automatically be converted to shares in Modus Therapeutics.

#### **If Your Warrants Are Directly Registered**

Subscription for new shares, through the exercise of warrants, shall be made by submitting a fully completed subscription form to Bergs Securities. Payment shall be made in connection with the submission of the subscription form to Bergs Securities, in accordance with the payment instructions on the subscription form. The completed subscription form and payment must be

received by Bergs Securities no later than 24 April 2026. Subscribed and paid shares will be registered in your CSD account as "interim shares" ("IA") until the registration of the new shares is completed at the Swedish Companies Registration Office (Bolagsverket), at which point interim shares will automatically be converted to shares in Modus Therapeutics.

### **This Information**

This information was submitted for publication, through the agency of the contact persons below, on 13 April 2026 at 08:00 CEST.

### **For more information on Modus Therapeutics, please contact:**

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: [john.ohd@modustx.com](mailto:john.ohd@modustx.com)

### **Certified Adviser**

Bergs Securities AB

Hemsida: [www.bergssecurities.se](http://www.bergssecurities.se)

### **About Modus Therapeutics and sevuparin**

Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at [www.modustx.com](http://www.modustx.com).

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

### **Attachments**

[Correction of Previously Communicated Press Release](#)